Extensive-stage small-cell lung cancer in patients receiving atezolizumab plus carboplatin-etoposide: stratification of outcome based on a composite score that combines gene expression profiling and immune characterization of microenvironment.

Anna TosiMartina LorenziPaola Del BiancoAnna RomaAlberto PavanAntonio ScapinelloMaria Vittoria ResiLaura BonannoStefano FregaFiorella CalabreseValentina GuarneriAntonio RosatoGiulia Pasello

Published in: Journal for immunotherapy of cancer (2024)

In conclusion, we identified tissue biomarkers and a combined score that can predict a higher benefit from chemoimmunotherapy in ES-SCLC patients.

Keyphrases

small cell lung cancer
end stage renal disease
genome wide
ejection fraction
newly diagnosed
chronic kidney disease
stem cells
peritoneal dialysis
copy number
gene expression
randomized controlled trial
patient reported outcomes
brain metastases
study protocol
phase iii
open label